These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 15568310

  • 21. [Measurement of the chemiluminescence of the urine and blood serum during the adverse effects of drugs on patients with tuberculosis].
    Shchutskaia EI, Priakhina VN, Kolpakova TA.
    Probl Tuberk; 1989; (1):55-9. PubMed ID: 2717593
    [Abstract] [Full Text] [Related]

  • 22. [Biochemical bases of adverse reactions to antibacterial preparations used in renal tuberculosis and means of their prevention].
    Kazakov KS, Chernik RB, Krivtsova MA.
    Probl Tuberk; 1989; (6):52-5. PubMed ID: 2771913
    [Abstract] [Full Text] [Related]

  • 23. [Recommendations to otolaryngologists for patients with antituberculotic chemotherapy (author's transl)].
    Rempt E.
    Z Erkr Atmungsorgane; 1981; 156(1):64-7. PubMed ID: 6971533
    [Abstract] [Full Text] [Related]

  • 24. [Correction of bronchial obstructive syndrome and antituberculous drugs-induced eosinophilia in patients with pulmonary tuberculosis by using plasmapheresis].
    Shmelev EI, Stepanian IE.
    Probl Tuberk; 1996; (6):57-60. PubMed ID: 9019774
    [Abstract] [Full Text] [Related]

  • 25. [Clinico-biochemical characteristics of adverse reactions to antibacterial drugs in patients with pulmonary tuberculosis].
    Kostina ZI, Shaposhnikov AM, Ivanovskiĭ VB.
    Probl Tuberk; 1978 Aug; (8):38-41. PubMed ID: 704581
    [No Abstract] [Full Text] [Related]

  • 26. [The use of fenazid in patients with pulmonary tuberculosis with poor isoniazid tolerance].
    Borisova MI, Stakhanov VA, Sharkova TI, Ivashchenko NA.
    Probl Tuberk Bolezn Legk; 2003 Aug; (7):34-7. PubMed ID: 12939876
    [Abstract] [Full Text] [Related]

  • 27. [Absorption of nutrients in patients with pulmonary tuberculosis].
    Ginzburg VS, Dadamukhamedov AA.
    Probl Tuberk; 1990 Aug; (10):44-6. PubMed ID: 2080159
    [Abstract] [Full Text] [Related]

  • 28. [The course of a process and the efficiency of treatment of pulmonary tuberculosis patients excreting Mycobacterium tuberculosis with extensive drug resistance to antituberculous drugs].
    Mishin VIu, Komissarova OG, Chukanov VI, Kononets AS.
    Probl Tuberk Bolezn Legk; 2009 Aug; (2):50-2. PubMed ID: 19382643
    [Abstract] [Full Text] [Related]

  • 29. [Frequency and character of side effects of anti-tubercular drugs].
    Kazakov KS, Kalankhodzhaev AA, Kozarez MI, Atamatov KhA, Mukhtarov DZ, Ikramova MI, Gamzaeva NF, Magrupov IaA.
    Probl Tuberk; 1991 Aug; (12):28-31. PubMed ID: 1803369
    [Abstract] [Full Text] [Related]

  • 30. [Prevention of adverse reactions of antituberculous drugs in pulmonary tuberculosis in patients with different genetic background].
    Tashpulatova FK.
    Probl Tuberk Bolezn Legk; 2003 Aug; (5):50-1. PubMed ID: 12899021
    [Abstract] [Full Text] [Related]

  • 31. [Frequency, pattern, and diagnosis of adverse reactions in patients with pulmonary tuberculosis during chemotherapy with leading drugs].
    Mishin VIu, Vasil'eva IA, Makieva VG, Kuz'mina NV, Prikazchikova AV, Khoroshutina VV.
    Probl Tuberk Bolezn Legk; 2003 Aug; (7):24-9. PubMed ID: 12939872
    [Abstract] [Full Text] [Related]

  • 32. High levels of resistance to second-line anti-tuberculosis drugs among prisoners with pulmonary tuberculosis in Georgia.
    Jugheli L, Rigouts L, Shamputa IC, Bram de Rijk W, Portaels F.
    Int J Tuberc Lung Dis; 2008 May; 12(5):561-6. PubMed ID: 18419893
    [Abstract] [Full Text] [Related]

  • 33. [Intolerance to antituberculous drugs and methods of its elimination].
    Rudoi NM, Smailova GA, Mardanov SK.
    Probl Tuberk; 1991 May; (6):32-5. PubMed ID: 1780306
    [Abstract] [Full Text] [Related]

  • 34. [Efficiency of a new standard chemotherapy regimen in the treatment of patients with recurrent pulmonary tuberculosis].
    Chukanov VI, Komissarova OG, Maishin VIu, Abdullaev RIu, Kononets AS.
    Probl Tuberk Bolezn Legk; 2006 May; (8):9-13. PubMed ID: 17002050
    [Abstract] [Full Text] [Related]

  • 35. Treatment with capreomycin, with special reference to toxic effects.
    Hesling CM.
    Tubercle; 1969 Mar; 50():Suppl:39-41. PubMed ID: 5402544
    [No Abstract] [Full Text] [Related]

  • 36. [Results of use of surfactant in complex therapy of patients with destructive pulmonary tuberculosis].
    Lovacheva OV, Erokhin VV, Chernichenko NV, Evgushchenko GV, Lepekha LN, Rozenberg OA.
    Probl Tuberk Bolezn Legk; 2006 Mar; (10):12-7. PubMed ID: 17139825
    [Abstract] [Full Text] [Related]

  • 37. [Multidrug pulmonary tuberculosis: sociomedical features and the efficiency of inpatient treatment].
    Filiniuk OV, Ianova GV, Strelis AK, Urazova OI, Zemlianaia NA, Buĭnova LN, Voronkova OV, Ianov SA, Shchegertsov DIu.
    Probl Tuberk Bolezn Legk; 2008 Mar; (8):23-8; discussion 28. PubMed ID: 18819334
    [Abstract] [Full Text] [Related]

  • 38. [Effect of stellate ganglion block in tinnitus and hearing disorders in patients with pulmonary tuberculosis].
    Akagami Y, Nishimura N.
    Masui; 1969 Dec; 18(13):1508-10. PubMed ID: 5391680
    [No Abstract] [Full Text] [Related]

  • 39. [Adverse effects of multi-drug therapy in patients with tuberculosis and ways of their correction].
    Gel'berg IS, Vol'f SB, Vrublevskaia NI, Pigalkova EN, Krotkova EN, Shevchuk DV, Avlasenko VS.
    Probl Tuberk; 2002 Dec; (4):12-6. PubMed ID: 12125243
    [Abstract] [Full Text] [Related]

  • 40. [Excretion of catecholamines and DOPA in the urine of patients with pulmonary tuberculosis during chemotherapy].
    Prosvetov IuV.
    Probl Tuberk; 1989 Dec; (10):46-9. PubMed ID: 2512573
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.